BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma, J Clin Oncol, vol.30, pp.2522-2529, 2013. ,
BRAF in melanoma: current strategies and future directions, Clin Cancer Res, vol.19, pp.4326-4334, 2013. ,
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032, J Transl Med, vol.14, p.67, 2010. ,
Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing, PLoS ONE, vol.8, p.70826, 2013. ,
Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions, Am J Surg Pathol, vol.37, pp.413-420, 2013. ,
Detection of BRAF p. V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing, J Mol Diagn, vol.15, pp.94-100, 2013. ,
Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma, Mod Pathol, vol.26, pp.414-420, 2013. ,
Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients, J Invest Dermatol, vol.133, pp.1378-1381, 2013. ,
Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p. V600E and non-p.V600E BRAF mutations, BMC Cancer, vol.14, p.13, 2014. ,
Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma, Am J Surg Pathol, vol.37, pp.61-65, 2013. ,
BRAF V600E mutation-specific antibody: a review, Semin Diagn Pathol, vol.pii, issue.15, pp.11-19, 2015. ,
Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in papillary thyroid carcinoma. Comparative analysis with three DNA-based assays, Thyroid, vol.24, pp.858-866, 2014. ,
Quantitative and sensitive detection of rare mutations using droplet-based microfluidics, Lab Chip, vol.11, pp.2156-2166, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-02148770
Immunohistochemistry and personalised medicine in lung oncology: advantages and limitations, Bull Cancer, vol.101, pp.958-965, 2014. ,
BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma, Br J Cancer, vol.108, pp.924-931, 2013. ,
Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations, Br J Cancer, vol.109, pp.2833-2841, 2013. ,
Intra-patient heterogeneity of BRAF mutation status: fact or fiction?, Br J Cancer, vol.111, pp.1678-1679, 2014. ,
Intrapatient homogeneity of BRAFV600E expression in melanoma, Am J Surg Pathol, vol.38, pp.377-382, 2014. ,
Inter-and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma, PLoS ONE, vol.9, p.85004, 2014. ,
Intra-and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma, PLoS ONE, vol.7, p.29336, 2012. ,
Accurate detection of BRAF p. V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays, Hum Pathol, vol.45, pp.2281-2293, 2014. ,
Pitfalls in lung cancer molecular pathology: how to limit them in routine practice, Curr Med Chem, vol.19, pp.2638-2651, 2012. ,
The accreditation of a surgical pathology and somatic genetic laboratory (LPCE, CHU of Nice) according to the ISO 15189 norm°haring of experience, Ann Pathol, vol.33, pp.386-397, 2013. ,
Success and failure rates of tumor genotyping techniques in routine pathological samples with nonsmall-cell lung cancer, Lung Cancer, vol.84, pp.39-44, 2014. ,
Assessment of morphology, antigenicity, and nucleic acid integrity for diagnostic thyroid pathology using formalin substitute fixatives, Thyroid, vol.19, pp.1239-1248, 2009. ,
Molecular markers in melanoma, Br J Dermatol, vol.170, pp.31-35, 2014. ,
Clinicopathological relevance of BRAF mutations in human cancer, Pathology, vol.45, pp.346-356, 2013. ,
Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group, BMC Cancer, vol.13, p.472, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-00873750
Current landscape and new paradigms of proficiency testing and external quality assessment for molecular genetics, Arch Pathol Lab Med, vol.137, pp.983-988, 2013. ,
Detection of BRAF p. V600E mutations in melanoma by immunohistochemistry has a good interobserver reproducibility, Arch Pathol Lab Med, vol.138, pp.71-75, 2014. ,